<DOC>
	<DOC>NCT02242461</DOC>
	<brief_summary>We hypothesize that add-on Rhodiola L extract capsule to the regimen of patients with moderate-to-severe COPD (1) may provide a potential of systemic effects of anti-inflammation and anti-oxidation for these patients, and these effects (2) may reflect in the improvement of patients' physiological measurements, quality of life and exercise tolerance.</brief_summary>
	<brief_title>Rhodiola Crenulata as an Adjunctive Therapy in COPD</brief_title>
	<detailed_description>This is a single center, randomized, double-blind, placebo controlled clinical trial. Eligibility criteria: 1. moderate-to-severe COPD patients 2. aged 40-80 years, 3. abstaining from cigarette smoking or maintaining a stable dose of cigarette consumption, 4. no acute exacerbation of COPD, 5. clinically being stable for one month and longer, 6. not undergoing exercise training program. Primary endpoint: six-minute walk distance in meters at week 12.</detailed_description>
	<criteria>1. moderatetosevere COPD patients 2. aged 4080 years, 3. abstaining from cigarette smoking or maintaining a stable dose of cigarette consumption, 4. no acute exacerbation of COPD, 5. clinically being stable for one month and longer, 6. not undergoing exercise training program. 1. uncontrolled diabetes mellitus by plasma fasting sugar &gt;200 mg/dl, 2. uremia or CKD stage 5, 3. chronic heart failureby NYFC III, 4. cerebrovascular disease, 5. uncontrolled anemia by Hb &lt; 10 mg/dl, 6. active malignant diseases, 7. other hospitalized acute illness, 8. systemic prednisolone &gt; 10 mg per day.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>COPD, Rhodiola L., clinical trial, biomarkers, spirometry</keyword>
</DOC>